Objective-Antiangiogenic activity of thrombospondin-1 and related proteins is mediated by interactions between thrombospondin type 1 repeat (TSR) domains and the CD36, LIMP-2, Emp sequence homology (CLESH) domain of the endothelial cell receptor CD36. We sought to characterize key molecular determinants of the interaction between thrombospondin-1 TSR domains and the CD36 CLESH domain. Approach and Results-Recombinant thrombospondin-1 TSR2 and TSR(2,3) constructs inhibited microvascular endothelial cell migration, microvascular endothelial cell tube formation, and vessel sprouting in aortic ring assays. Interaction with CD36 CLESH decoy peptides negated these effects. Mutational analyses identified a cluster of residues that confer positive charge to the TSR2 surface and mediate interaction with CD36 CLESH. Antiangiogenic activity was significantly reduced by charge-neutralizing mutations of the Arg-Trp ladder in TSR2, but not TSR3. Additionally, I438 and K464 of TSR2 were shown to be required for CD36 CLESH binding to TSR2. A complementary acidic cluster within CD36 CLESH is also required for antiangiogenic activity. Conclusions-Thrombospondin-1 interacts with CD36 CLESH through electrostatic interactions mediated by a positively charged TSR2 surface and multiple negatively charged CD36 CLESH residues. Two key residues serve as specificity determinants that identify other TSR domains that interact with CD36 CLESH. (Arterioscler Thromb Vasc Biol. 2013;33:1655-1662.)
T he matricellular protein thrombospondin-1 (TSP-1) was the first endogenous protein inhibitor of angiogenesis to be identified. 1 TSP-1, first isolated from human platelets, 2 inhibits endothelial cell proliferation 3 and migration and promotes apoptosis in the context of proangiogenic signals. 4, 5 At early stages of dermal wound healing, TSP-1 is released from platelet alpha granules into thrombi and the extracellular matrix to delay vascular remodeling. 6 Within the tumor microenvironment, downregulation of TSP-1 is critical for many tumor cell types to continue unregulated cellular growth, metastasis, and seeding to secondary sites. 7 Among the 5 members of the thrombospondin family, only TSP-1 and TSP-2 have been shown to have antiangiogenic activity to date. The functions of TSP-3 and TSP-4 are currently unclear. TSP-5, also called cartilage oligomeric matrix protein, regulates attachment and survival of chondrocytes and potentially of other musculoskeletal cells, [8] [9] [10] [11] but no angiogenic functions for this protein have been reported.
TSP-1 and TSP-2 each contain 3 highly homologous thrombospondin type 1 repeat (TSR) domains. The other members of the thrombospondin family do not contain TSRs, emphasizing that TSR domains are important for antiangiogenic function. Furthermore, several other antiangiogenic proteins, such as brain angiogenesis inhibitor-1 (BAI1), also contain TSR domains. The best-studied TSRs, the second and third TSR domains of TSP-1 (called TSR [2, 3] ), bind and activate transforming growth factor-β, [12] [13] [14] [15] [16] bind heparan sulfate proteoglycans and fibronectin, 7 and promote endothelial cell apoptosis through the cell surface receptor CD36. 17, 18 Recombinant TSR domains and TSR-derived synthetic peptides exhibit potent antiangiogenic activity within tumors 19 and attenuate tumor growth in mice. [20] [21] [22] Although TSR-derived peptides have been tested in phase II clinical trials, results are mixed. 23 A more detailed understanding of the structural mechanisms used by TSR domains to regulate angiogenesis may inform the design of future therapies against pathological angiogenesis.
Two available crystal structures of TSP-1-TSR(2,3) 11,24 showcase a positively charged surface ridge within each TSR. These ridges have been proposed to serve as a recognition surface for TSP-1 and TSP-2 binding partners, 25 most notably CD36. A ≈30-residue-long region within CD36 called the CLESH (CD36, LIMP-2, Emp sequence homology) domain is sufficient for TSR binding. 26 We and others have suggested that the negatively charged CLESH domain interacts with TSR domains via the positively charged surface ridge. 11, 27 Moreover, we reported that phosphorylation of a CD36 threonine adjacent to the CLESH domain negatively regulates TSP-1 binding. 27 The basis and extent of TSR/CD36 CLESH interactions, however, remain poorly defined.
In the present study, we characterize the molecular basis of interaction between the TSR domains of TSP-1 and the CD36 CLESH domain. We show that only the TSR2 of TSP-1 binds to the CD36 CLESH domain to inhibit microvascular endothelial cell (MVEC) angiogenic functions. We propose and validate key specificity determinants that mediate the interaction of TSR2 with CD36 CLESH and allow for the identification of other TSR domains that interact with CD36 CLESH. This study provides a framework to better understand the CD36 CLESH/TSR binding interface and the molecular determinants that mediate TSP-1 binding to CD36 at the endothelial cell surface.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

TSR2 Charge-Neutralizing Mutations Abolish the TSP-1/CD36 CLESH Interaction
The TSR2 and TSR3 of TSP-1 were previously identified as the domains responsible for antiangiogenic inhibition of MVEC-d migration. 24, 28 Sequence analyses have also identified TSR domains within the antiangiogenic proteins TSP-2, BAI1, and a disintegrin and metalloproteinase with thrombospondin motifs 1 and 4 (ADAMTS-1 and ADAMTS-4). Two conserved arginine residues ( Figure 1A ) participate in cation-π stacking with neighboring tryptophan residues to form the Cysteine, Tryptophan, Arginine (CWR)-layered core of each TSR domain. 24, 25 These arginine residues confer a positive charge to 1 surface ridge of the CWR-layered core ( Figure 1B ). On the basis of electrostatic surface calculations and molecular modeling, we hypothesized that novel Arg-to-Met mutations could reduce the positive charge of the CWR-layered core surface ridge ( Figure 1B ; Figure I in the online-only Data Supplement) without compromising the structural integrity of the TSRs.
We analyzed the effect of individual Arg-to-Met mutations of TSR(2,3) on the inhibition of MVEC-d migration in a modified Boyden chamber assay. Few cells migrated when incubated against a low growth factor media chemoattractant containing 10% of normal growth factors ( Figure 1C ). Incubation against a normal growth factor media chemoattractant containing 100% of normal growth factors resulted in a 5-fold increase in migration. Addition of recombinant TSR(2,3) to normal growth factor media reduced MVEC-d migration to a level similar to that observed with low growth factor media. Arg-to-Met mutations in the TSR2 domain (R440M and R442M) fully abrogated the inhibitory activity of TSR (2, 3) . In contrast, the equivalent Arg-to-Met mutations in the TSR3 domain (R497M or R499M) had no significant effect on the inhibitory activity of TSR (2, 3) .
Because the effect of Arg-to-Met mutations could be ascribed to disruptions in the structure of TSR2, we acquired solution nuclear magnetic resonance heteronuclear single quantum coherence (NMR HSQC) spectra for uniformly 15 N-labeled wild-type, R440M-and R442M-TSR2. HSQC spectra for R440M-and R442M-TSR2 are well dispersed and very similar to the HSQC spectrum of wild-type TSR2 ( Figure II in the online-only Data Supplement), verifying that the R440M Figure 1 . Conserved arginine residues in thrombospondin type I repeat 2 (TSR2) are required for the antimigratory activity of TSR (2, 3) . A, Sequence alignment of the second and third TSR domains of TSR(2,3) against TSR-containing proteins with antiangiogenic activity. Conserved arginine (cyan) and tryptophan (magenta) residues within the CWR-layered core are highlighted. B, APBS-calculated electrostatic surface representations of wildtype and Arg-to-Met mutant TSR2 or TSR3. Molecular surfaces are colored according to the solvent accessible surface potential from +5 kT (blue) to -5 kT (red). C, Modified Boyden chamber migration assay of microvascular endothelial cell (MVEC)-d detected by DAPI staining. MVEC-d was allowed to migrate toward low growth factor media (low GF) or media containing a full complement of growth factors (normal GF). MVEC-d migration assays performed in the presence of recombinant wild-type or Arg-to-Met mutant TSR(2,3) were allowed to migrate toward media containing a full complement of growth factors. Data represent mean±SD of 3 independent experiments (**P<0.001). and R442M mutations do not substantially alter the tertiary structure of TSR2.
TSR2 Is the Critical TSR Required for CD36 CLESH Binding
To confirm that TSR2 is the minimal domain responsible for the CD36 CLESH-dependent antimigratory activity of TSP-1, we conducted MVEC-d migration assays with TSR(2,3), TSR2, and TSR3 domain constructs. TSR2 attenuated MVEC-d migration to the same extent as the TSR(2,3) construct ( Figure 2A ). Attenuation of MVEC-d migration by TSR2 was reversed on addition of a competing GST-CD36 CLESH fusion protein, whereas GST alone had no effect ( Figure 2A ). In comparison, only TSR3 mildly attenuated MVEC-d migration and this attenuation was insensitive to CD36 CLESH (Figure 2A ).
We next performed solid-phase binding assays to directly measure binding of CD36 CLESH to TSR(2,3), TSR2, or TSR3. In a binding assay using CD36 CLESH-ubiquitin fusion protein (CLESH-Ub) probed with an anti-ubiquitin antibody, the CLESH-Ub fusion bound similarly to TSR2 and TSR(2,3) ( Figure 2B ). We observed minimal binding of CLESH-Ub to TSR3 or in a control experiment measuring binding of ubiquitin to TSR2. . Thrombospondin type I repeat 2 (TSR2), but not TSR3, exhibits CD36-CLESH-dependent antiangiogenic activity in microvascular endothelial cell (MVEC) tube formation and aortic ring assays. A, MVECs-b were seeded onto Matrigel and incubated for 6 hours with a low growth factor media (low GF), media with full complement of growth factors (normal GF), or full growth factor media in the presence of TSR2, TSR2, and CD36 CLESHubiquitin (TSR2+CLESH), TSR3 or TSR3 and CD36 CLESH-Ub (TSR3+CLESH). Tube formation was assessed by counting the number of branch points per 10× field as detected by phase contrast microscopy. B, Aortic rings were cultured in Matrigel with media containing a full complement of growth factors (normal GF), or full media containing recombinant wild-type TSR2, TSR2 and CD36 CLESH-Ub (TSR2+CLESH), TSR3 or TSR3 and CD36 CLESH-Ub (TSR3+CLESH). Total vessel formation per aortic ring after 6 days was assessed by phase contrast micro scopy. Data represent mean±SD of 3 independent experiments (**P<0.001; *P<0.01). N.S. indicates no significant difference. July 2013
TSR2, but Not TSR3, Inhibits Angiogenesis in a CD36 CLESH-Dependent Manner
Solid-phase binding assays and MVEC-d migration assays suggested that TSR2 exhibits CD36 CLESH-dependent antiangiogenic activity, whereas TSR3 does not. To evaluate this hypothesis, we performed ex vivo angiogenesis assays that examined branching in MVEC-b tube formation 29, 30 and assessed vessel sprouting of aortic rings. 31 MVEC-b tube formation assays with TSR2 reduced tube formation to levels similar to that observed in low growth factor-containing media ( Figure 3A ; Figure III in the online-only Data Supplement).
Tube formation was fully restored by the addition of CD36 CLESH ( Figure 3A ). In comparison, TSR3 slightly inhibited MVEC-b tube formation; however, this inhibition was insensitive to CD36 CLESH ( Figure 3A ). TSR2 also significantly impaired vessel sprouting in an aortic ring assay ( Figure 3B ; Figure IV in the online-only Data Supplement). This inhibitory activity was reversed on addition of CD36 CLESH ( Figure 3B ). TSR3 had no significant effect on aortic ring vessel sprouting and exhibited no CD36 CLESH dependence ( Figure 3B ). Dashed lines indicate the cutoff values for residues exhibiting CSPs >3σ or 6σ above the noise. B, Significant CSPs mapped to the structure of TSR2 (white) shown in cartoon representation. Residues are colored corresponding to CSPs >3σ (cyan) or 6σ (blue) above the noise. C, Sequence alignment of the second and third TSR domains of TSR (2, 3) . Residues I438 and K464, which confer a positive charge to TSR2 and corresponding residues in TSR3, are highlighted (black). D, APBS-calculated electrostatic surface representations of wild-type TSR2, I438Q/K464Q mutant TSR2, wild-type TSR3, and Q495I/Q521K mutant TSR3 colored according to the solvent accessible surface potential from +5 kT (blue) to -5 kT (red). E, MVECs-d were allowed to migrate toward low growth factor media (low GF), media containing a full complement of growth factors (normal GF), or full media containing recombinant wild-type TSR(2,3), I438Q/K464Q-TSR(2,3), Q495I/Q521K-TSR3, or BAI1-TSR3 with or without CD36 CLESH. F, MVECs-b plated onto Matrigel were incubated for 6 hours against low growth factor media (low GF), media containing a full complement of growth factors (normal GF), or full growth factor media in the presence of Q495I/Q521K-TSR3 (TSR3 Q495I/Q521K) or Q495I/Q521K-TSR3 and CD36 CLESH (TSR3 Q495I/Q521K+CLESH). Tube formation was assessed by counting the number of branch points per 10× field as detected by phase contrast microscopy. G, Aortic rings were cultured in Matrigel with full growth factor media (normal GF), or full growth factor media with TSR2, Q495I/Q521K-TSR3 (TSR3 Q495I/Q521K) or Q495I/Q521K-TSR3 and CD36 CLESH (TSR3 Q495I/Q521K+CLESH). Total vessel formation per aortic ring after 6 days was assessed by phase contrast microscopy. Data represent mean±SD of 3 independent experiments (**P<0.001). N.S. indicates no significant difference.
Conversion of TSR2 to TSR3 Eliminates CD36 CLESH Effects
We performed solution NMR HSQC titrations to identify TSR2 residues that interact with CD36 CLESH or are located near the CLESH-binding site ( Figure 4A ). Such residues are predicted to exhibit chemical shift perturbations on addition of CLESH-Ub. As a control, we observed no significant chemical shift perturbations induced by ubiquitin alone (Figure 4A ). Residues that undergo significant chemical shift perturbations (>3σ above noise) cluster along the surface ridge of the CWRlayered core and a nearby pocket ( Figure 4B) . The NMR data, in combination with migration assay results for wild-type and Arg-to-Met mutant TSR(2,3) constructs, confirm that the positively charged surface ridge of the TSR2 CWR-layered core is a key determinant for CD36 CLESH binding.
We compared putative CLESH-interacting TSR2 residues that were identified in our NMR HSQC experiments with the sequence of TSR3. We identified 2 nonconserved residues, I438 and K464 ( Figure 4C ). These 2 amino acids contribute to the overall positive character of the CLESH-binding surface of TSR2 ( Figure 4D ). The corresponding residues in TSR3, Q495, and Q521 result in a more neutral surface ( Figure 4D ). We therefore introduced dual I438Q/K464Q mutations in TSR(2,3) to neutralize the CLESH-binding surface of TSR2 ( Figure 4D ). We also introduced dual Q495I/Q521K mutations in TSR3 to increase the overall positive character of TSR3 and produce a surface with similar charge characteristics as TSR2 ( Figure 4D ).
Although wild-type TSR(2,3) effectively inhibited MVEC-d migration, TSR(2,3)-I438Q/K464Q was only partly effective ( Figure 4E ). Furthermore, although CD36 CLESH blocked the inhibition of MVEC-d migration by wild-type TSR(2,3), it had no effect on TSR(2,3)-I438Q/K464Q ( Figure 4E ). In contrast, TSR3-Q495I/Q521K effectively inhibited migration, and this inhibitory activity was sensitive to CD36 CLESH ( Figure 4E ). These results suggest that Q495I/Q521K mutations within TSR3 were sufficient to confer CD36 CLESH sensitivity to a TSR domain. We tested whether this converted TSR domain also exhibits antiangiogenic activity similar to wild-type TSR2 (Figure 3 ). MVEC-b tube formation assays ( Figure 4F ) and aortic ring assays ( Figure 4G ) confirmed the CD36 CLESH-dependent antiangiogenic activity of TSR3-Q495I/Q521K. These results suggest that the I438/K464 and Q495/Q521 pockets contribute significantly to the surface charge characteristics of the TSR domains, and that these residues represent key molecular determinants for CD36 CLESHdependent antiangiogenic activity.
Sequence alignments of TSR domains from proteins with antiangiogenic activity ( Figure 1A ; Figure V in the onlineonly Data Supplement) identify TSP-2 TSR2 and BAI1 TSR3 as positively charged TSR domains similar to TSP-1 TSR2. We tested whether BAI1 TSR3 exhibits antimigratory activity in a CD36 CLESH-dependent manner ( Figure 4E ). BAI1 TSR3 effectively inhibited MVEC-d migration in a manner similar to TSP-1 TSR(2,3). Additionally, CD36 CLESH significantly reduced BAI1 TSR3 inhibition of MVEC-d migration.
Acidic Residues in CD36 CLESH Are Critical for Interaction With TSR2
The CD36 CLESH domain has 4 acidic residues, E101, D106, E108, and D109 ( Figure 5A) , that potentially interact with the positively charged CLESH-binding surface of TSR2. We therefore tested individual and multiple alanine mutations of these amino acids in MVEC-d migration assays. Although wild-type CD36 CLESH blocked the inhibition of MVEC-d migration by TSR2 ( Figure 5A; TSR2+CLESH) , the E101A-, D106A-, E108A-, and D109A-CD36 CLESH mutants only partly rescued MVEC-d migration ( Figure 5B ). Furthermore, the triple mutant D106A/E108A/D109A-and quadruple mutant E101A/D106A/E108A/D109A-CD36 CLESH did not rescue MVEC migration at all ( Figure 5B ). In combination with NMR binding studies (Figure 4) , these data show that the CD36 CLESH acidic side chains mediate the interaction between CD36 CLESH and the positively charged surface of TSR2.
Position 92 of the Extended CD36 CLESH Domain Regulates Interaction With TSR2
Our laboratory previously demonstrated that phosphorylation of the extended CD36 CLESH domain at T92 ( Figure 5A ) significantly blocked TSP-1 binding in an in vitro ELISA assay. 27 Mutagenesis of CD36 suggested a steric component to the inhibition of CD36/TSP-1 interactions by T92 phosphorylation. 27 To further explore this possibility, we performed MVEC-d migration assays in the presence of TSR2 and CD36 CLESH in which T92 is substituted by tryptophan, glutamate or arginine, amino acids with bulky side chains and a range of charge states. In comparison with wild-type CD36 CLESH, T92W-, T92E-, or T92R-CD36 CLESH only partly restored MVEC-d migration blocked by TSR2 ( Figure 5B) . The similar effect of neutral, negatively charged, and positively charged bulky side-chain substitutions at T92 suggest that phosphorylation of T92 may sterically rather than electrostatically interfere with CD36 CLESH/TSP-1 interactions.
Molecular Model of the TSR2/ CD36 CLESH Complex
Our MVEC-d migration assays and in vitro ELISA and NMR binding studies provide residue-specific restraints that can be used to model the interaction between TSR2 and CD36 CLESH. We prepared a list of ambiguous restraints in which each TSR2 residue found by migration assays, ELISA or NMR, contributes to CD36 CLESH binding was restrained to a distance of ≤3.5 Å from E101, D106, E108, or D109 of CD36 CLESH. Complementary restraints required these CD36 CLESH residues to be positioned at ≤3.5 Å from TSR2 residues found to contribute to CD36 CLESH binding. We used these ambiguous restraints as an input for a rigid body/ torsion angle dynamics simulated annealing protocol to generate a model of the TSR2/CD36 CLESH complex. Consistent with the results of MVEC migration assays for the R440M, R442M, I438Q, and K464Q TSR(2,3) mutants, the model suggests that the interaction between CD36 and TSP-1 is mediated by extensive electrostatic contacts between negatively charged CD36 CLESH carboxylate side chains and residues that confer a positive charge to TSR2 ( Figure 6 ).
Discussion
Although the interactions between TSP-1 TSR domains and the CD36 CLESH domain are central to the CD36-dependent antiangiogenic and antimigratory activities of TSP-1, 26, 27 the molecular basis for the TSP-1/CD36 CLESH interaction has been poorly defined to date. In this study, we combined structural and sequence data, mutagenesis, protein-protein interaction experiments, and in vitro functional assays to characterize key determinants that regulate TSR interactions with CD36 CLESH.
Our NMR experiments identified a cluster of TSR2 surface residues that were perturbed on addition of CD36 CLESH, suggesting a direct contact with the CD36 CLESH domain. Corneal pocket and endothelial cell migration assays previously implicated these residues in TSP-1 antiangiogenic activity. 17, 32 Using molecular modeling, we identified an allowed side-chain rotamer for methionine that places the methionine δ-sulfur atom in a position for S-π interactions [33] [34] [35] and preserves the π-stacking arrangement with neighboring tryptophan indole rings. The arginine to methionine substitutions within the CWR-layered cores of TSR2 and TSR3 likely neutralize the charged WR-stacking motif surface ridges. We indeed observed that these mutations disrupt TSR2 interactions with CD36 CLESH.
In contrast to the highly conserved WR-stacking motif, an I-K positively charged patch on TSR2 formed by I438 and K464 serves as a differentiating factor between TSR2 and TSR3. The I-K patch is a key determinant that can be used to identify CD36 CLESH-interacting TSR domains on the basis of amino acid sequence ( Figure V in the online-only Data Supplement). We hypothesize that among the 5 TSRcontaining proteins with known antiangiogenic activity, only TSP-1 TSR2, TSP-2 TSR2, and BAI1 TSR3 contain the necessary determinants for interacting with CD36 CLESH. These 3 TSR domains contain residues with side chains that would confer a positive charge to the I-K patch, whereas other TSR domains within these proteins contain neutral patches that are likely unsuitable for CD36 CLESH binding. The TSRcontaining fragment of BAI1 was previously identified as an inhibitor of intracranial glioma growth and progression through a CD36-dependent mechanism. 36 Our I-K patch sequence-based categorizations predict that BAI1 TSR3 is responsible for BAI1 antiangiogenic activity, consistent with previous reports from our laboratory and others. 37 Indeed, we found that BAI1 TSR3 suppressed endothelial cell migration, and this inhibition was partly reversed by CD36 CLESH ( Figure 4E ). In contrast, the TSR domains of ADAMTS-1 and ADAMTS-4 contain sequence differences that neutralize both the I-K patch and the WR-stacking motif, and most likely do not interact with CD36 CLESH.
Our modeling suggests that the CD36 CLESH sequence binds in an extended conformation along the positively charged TSR surface. Our NMR and mutagenesis data show that both electrostatic and steric determinants (eg, the phosphorylation state of T92) regulate TSR/CLESH binding. Interestingly, NMR titrations of 15 N-CD36 CLESH with TSR2 suggest that CD36 CLESH remains unstructured and dynamic in the presence of TSR2 (data not shown). We speculate that CD36 CLESH may interact with TSR2 as an ensemble of conformations that satisfy overall electrostatic complementarity without enforcing rigid pairwise interactions between specific CD36 CLESH and TSR2 residues. The distributed electrostatic nature of the TSR2/CD36 CLESH interaction is consistent with the relatively small chemical shift perturbations observed in our NMR experiments. Such a fuzzy interaction hypothesis 38 requires further investigation. However, it is noteworthy that the circulating protein histidine-rich glycoprotein also contains a CLESH-like domain that interacts with TSP-1 TSR domains. Although the histidine-rich glycoprotein CLESH contains a similar number of acidic residues as the CD36 CLESH, its acidic residues are located in a different arrangement than in CD36. 39 Interestingly, TSP1-TSR3 exhibited mild but reproducible antiangiogenic activity that is independent of CD36 CLESH. The mechanism by which TSR3 exerts this effect is not known. TSR3 may interact with a distinct region of CD36, with a distinct endothelial receptor or with an extracellular signaling factor. The characterization of the mode of action of TSR3 will require further study.
The identification of TSR2 as the source of CD36 CLESH-mediated antiangiogenic activity is relevant for the development of thrombospondin-based therapeutics. A recombinant TSP-1 construct containing the TSR1, TSR2, and TSR3 domains 19, 40 inhibited growth of human pancreatic cancer cells in an orthotopic mouse model. 40 However, this construct contains multiple epitopes that interact with distinct signaling pathways, including activation of transforming growth factor-β, via the Arginine, Phenylalanine, Lysine (RFK) motif located between TSR1 and TSR2. [12] [13] [14] [15] [16] Peptidomimetics modeled on sequences within TSP-1 TSR2 had limited success as a result of rapid clearance. 22 Although these peptide therapeutics were based on putative CD36-interacting epitopes, they most likely act through an entirely different pathway by activating transforming growth factor-β. 22 We hypothesize that these differences are attributable to the unusual structure of the TSR domains and the inability of small peptides to fully recapitulate the positively charged surface ridge required for binding to CD36 CLESH.
The results of the present study identify molecular determinants that regulate the CD36 CLESH-dependent antiangiogenic acitvity of TSP-1. The identification and characterization of the antiangiogenic properties of recombinant, bacterially expressed TSR domains like TSP1-TSR2 and BAI1 TSR3 may contribute further to the development of TSR-based therapies in malignant gliomas and other cancers.
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